1. Home
  2. AHCO vs DMRA Comparison

AHCO vs DMRA Comparison

Compare AHCO & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AdaptHealth Corp.

AHCO

AdaptHealth Corp.

HOLD

Current Price

$12.81

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$24.85

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AHCO
DMRA
Founded
2012
2011
Country
United States
United States
Employees
N/A
7
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
AHCO
DMRA
Price
$12.81
$24.85
Analyst Decision
Strong Buy
Buy
Analyst Count
4
1
Target Price
$13.50
$46.00
AVG Volume (30 Days)
1.2M
217.1K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,244,857,000.00
N/A
Revenue This Year
$9.00
N/A
Revenue Next Year
$6.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.91
$16.50
52 Week High
$12.87
$28.76

Technical Indicators

Market Signals
Indicator
AHCO
DMRA
Relative Strength Index (RSI) 67.91 46.18
Support Level $8.72 $23.65
Resistance Level N/A $28.00
Average True Range (ATR) 0.42 2.13
MACD -0.02 -0.14
Stochastic Oscillator 96.80 28.16

Price Performance

Historical Comparison
AHCO
DMRA

About AHCO AdaptHealth Corp.

AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: